Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 135

1.

Prospective Evaluation of Self-Reported Aggression in Transgender Persons.

Defreyne J, T'Sjoen G, Bouman WP, Brewin N, Arcelus J.

J Sex Med. 2018 May;15(5):768-776. doi: 10.1016/j.jsxm.2018.03.079.

PMID:
29699761
2.

Pro- and Anti-androgenic Progestins in Transgender Youth: Differential Effects on Body Composition and Bone Metabolism.

Tack LJW, Craen M, Lapauw B, Goemaere S, Toye K, Kaufman JM, Vandewalle S, T'Sjoen G, Zmierczak HG, Cools M.

J Clin Endocrinol Metab. 2018 Apr 16. doi: 10.1210/jc.2017-02316. [Epub ahead of print]

PMID:
29672753
3.

Routine histopathological examination after female-to-male gender-confirming mastectomy.

Van Renterghem SMJ, Van Dorpe J, Monstrey SJ, Defreyne J, Claes KEY, Praet M, Verbeke SLJ, T'Sjoen GGR, Van Bockstal MR.

Br J Surg. 2018 Jun;105(7):885-892. doi: 10.1002/bjs.10794. Epub 2018 Apr 5.

PMID:
29623678
4.

Prospective evaluation of hematocrit in gender-affirming hormone treatment: results from European Network for the Investigation of Gender Incongruence.

Defreyne J, Vantomme B, Van Caenegem E, Wierckx K, De Blok CJM, Klaver M, Nota NM, Van Dijk D, Wiepjes CM, Den Heijer M, T'Sjoen G.

Andrology. 2018 Mar 30. doi: 10.1111/andr.12485. [Epub ahead of print]

PMID:
29602229
5.

YSEX? A Replication Study in Different Age Groups.

Wyverkens E, Dewitte M, Deschepper E, Corneillie J, Van der Bracht L, Van Regenmortel D, Van Cleempoel K, De Boose N, Prinssen P, T'Sjoen G.

J Sex Med. 2018 Apr;15(4):492-501. doi: 10.1016/j.jsxm.2018.02.012. Epub 2018 Mar 14.

PMID:
29550464
6.

Growth, sexual and bone development in a boy with bilateral anorchia under testosterone treatment guided by the development of his monozygotic twin.

Vandewalle S, Van Caenegem E, Craen M, Taes Y, Kaufman JM, T'Sjoen G.

J Pediatr Endocrinol Metab. 2018 Mar 28;31(3):361-367. doi: 10.1515/jpem-2017-0126.

PMID:
29353265
7.

Effect of Continuous Glucose Monitoring on Glycemic Control, Acute Admissions, and Quality of Life: A Real-World Study.

Charleer S, Mathieu C, Nobels F, De Block C, Radermecker RP, Hermans MP, Taes Y, Vercammen C, T'Sjoen G, Crenier L, Fieuws S, Keymeulen B, Gillard P; RESCUE Trial Investigators.

J Clin Endocrinol Metab. 2018 Mar 1;103(3):1224-1232. doi: 10.1210/jc.2017-02498.

PMID:
29342264
8.

Neural correlates of ostracism in transgender persons living according to their gender identity: a potential risk marker for psychopathology?

Mueller SC, Wierckx K, Boccadoro S, T'Sjoen G.

Psychol Med. 2018 Jan 15:1-8. doi: 10.1017/S0033291717003828. [Epub ahead of print]

PMID:
29334035
9.

ENDOCRINE TREATMENT OF GENDER-DYSPHORIC/GENDER-INCONGRUENT PERSONS: AN ENDOCRINE SOCIETY CLINICAL PRACTICE GUIDELINE.

Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG.

Endocr Pract. 2017 Dec;23(12):1437. doi: 10.4158/1934-2403-23.12.1437. No abstract available.

PMID:
29320642
10.

Effects of Sex Hormone Treatment on the Metabolic Syndrome in Transgender Individuals: Focus on Metabolic Cytokines.

Auer MK, Ebert T, Pietzner M, Defreyne J, Fuss J, Stalla GK, T'Sjoen G.

J Clin Endocrinol Metab. 2018 Feb 1;103(2):790-802. doi: 10.1210/jc.2017-01559.

PMID:
29216353
11.

The Need of Patient Involvement in Transgender Health Care Research.

T'Sjoen G, Motmans J, Arcelus J, Bouman W.

J Sex Med. 2017 Dec;14(12):1494-1495. doi: 10.1016/j.jsxm.2017.09.019. No abstract available.

PMID:
29198506
12.

Changes in regional body fat, lean body mass and body shape in trans persons using cross-sex hormonal therapy: results from a multicenter prospective study.

Klaver M, de Blok CJM, Wiepjes CM, Nota NM, Dekker MJHJ, de Mutsert R, Schreiner T, Fisher AD, T'Sjoen G, den Heijer M.

Eur J Endocrinol. 2018 Feb;178(2):165-173. doi: 10.1530/EJE-17-0496. Epub 2017 Nov 28.

PMID:
29183889
13.

Breast Development in Transwomen After 1 Year of Cross-Sex Hormone Therapy: Results of a Prospective Multicenter Study.

de Blok CJM, Klaver M, Wiepjes CM, Nota NM, Heijboer AC, Fisher AD, Schreiner T, T'Sjoen G, den Heijer M.

J Clin Endocrinol Metab. 2018 Feb 1;103(2):532-538. doi: 10.1210/jc.2017-01927.

PMID:
29165635
14.

Malignant testicular germ cell tumors in postpubertal individuals with androgen insensitivity: prevalence, pathology and relevance of single nucleotide polymorphism-based susceptibility profiling.

Cools M, Wolffenbuttel KP, Hersmus R, Mendonca BB, Kaprová J, Drop SLS, Stoop H, Gillis AJM, Oosterhuis JW, Costa EMF, Domenice S, Nishi MY, Wunsch L, Quigley CA, T'Sjoen G, Looijenga LHJ.

Hum Reprod. 2017 Dec 1;32(12):2561-2573. doi: 10.1093/humrep/dex300.

PMID:
29121256
15.

Transgender Research in the 21st Century: A Selective Critical Review From a Neurocognitive Perspective.

Mueller SC, De Cuypere G, T'Sjoen G.

Am J Psychiatry. 2017 Dec 1;174(12):1155-1162. doi: 10.1176/appi.ajp.2017.17060626. Epub 2017 Oct 20. Review.

PMID:
29050504
16.

Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.

Lacroix A, Gu F, Gallardo W, Pivonello R, Yu Y, Witek P, Boscaro M, Salvatori R, Yamada M, Tauchmanova L, Roughton M, Ravichandran S, Petersenn S, Biller BMK, Newell-Price J; Pasireotide G2304 Study Group.

Lancet Diabetes Endocrinol. 2018 Jan;6(1):17-26. doi: 10.1016/S2213-8587(17)30326-1. Epub 2017 Oct 12. Erratum in: Lancet Diabetes Endocrinol. 2018 Jan;6(1):e1.

PMID:
29032078
17.

Healthcare costs and quality of life outcomes following gender affirming surgery in trans men: a review.

Defreyne J, Motmans J, T'sjoen G.

Expert Rev Pharmacoecon Outcomes Res. 2017 Dec;17(6):543-556. doi: 10.1080/14737167.2017.1388164. Epub 2017 Oct 9. Review.

PMID:
28972413
18.

Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline.

Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG.

J Clin Endocrinol Metab. 2017 Nov 1;102(11):3869-3903. doi: 10.1210/jc.2017-01658.

PMID:
28945902
19.

Transient Elevated Serum Prolactin in Trans Women Is Caused by Cyproterone Acetate Treatment.

Defreyne J, Nota N, Pereira C, Schreiner T, Fisher AD, den Heijer M, T'Sjoen G.

LGBT Health. 2017 Oct;4(5):328-336. doi: 10.1089/lgbt.2016.0190. Epub 2017 Sep 7.

PMID:
28880825
20.

Is Type 1 Diabetes Mellitus More Prevalent Than Expected in Transgender Persons? A Local Observation.

Defreyne J, De Bacquer D, Shadid S, Lapauw B, T'Sjoen G.

Sex Med. 2017 Sep;5(3):e215-e218. doi: 10.1016/j.esxm.2017.06.004. Epub 2017 Aug 1.

Supplemental Content

Loading ...
Support Center